# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN
- Date: 2026-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month follow-up on androgen deprivation, ten days before radiotherapy. **S**

## History of present illness

Mr. Mandela returns three months after his last visit, twelve weeks after his first leuprolide injection. He completed four weeks of bicalutamide. Hot flashes continue three or four times a week and are mild; his energy is a little lower in the afternoons, and he still walks every morning. His weight is up 1.2 kg since starting treatment. He has had no breast tenderness, chest pain, breathlessness, or leg swelling, and his mood and memory are unchanged. Fiducial markers were placed and the planning scans done a week ago, without complications. Radiotherapy starts in ten days. Urinary symptoms are unchanged. The audiology test after his wellness visit showed mild high-frequency hearing loss on the left, and he is thinking about a hearing aid. He takes vitamin D every day. **S**

| Element | Detail |
|---|---|
| Androgen deprivation | Twelve weeks on leuprolide; second injection given today |
| Side effects | Mild hot flashes; slightly lower afternoon energy; weight up 1.2 kg |
| Radiotherapy | Fiducial markers placed and planning done; treatment starts in ten days |
| Hearing | Mild high-frequency loss on the left on audiology |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly lower afternoon energy; weight up 1.2 kg |
| Endocrine | Positive | Mild hot flashes three or four times a week; no breast tenderness |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Psychiatric | Negative | Mood good; PHQ-2 score 1; no change in memory |

5 systems reviewed. **S**

## Current medications

- Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapy **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 81.6 kg; BMI 24.4 kg/m². All vital signs are synthetic.

PSA: 0.9 ng/mL; Total testosterone: 18 ng/dL (low); 25-hydroxyvitamin D: 34 ng/mL; PHQ-2: 1. All results are synthetic.

## Change since baseline

- PSA: 6.4 ng/mL (high) at baseline, 0.9 ng/mL at this visit **S**
- Total testosterone: 412 ng/dL at baseline, 18 ng/dL (low) at this visit **S**
- 25-hydroxyvitamin D: 26 ng/mL (low) at baseline, 34 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 134/78 mm Hg; no ankle swelling |
| Chest | No gynecomastia |
| Perineum | Fiducial insertion sites healed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Prostate cancer, unfavorable intermediate risk, on androgen deprivation before radiotherapy** (C61). PSA has fallen from 6.4 to 0.9 ng/mL on androgen deprivation, as expected. **S**
   - Radiotherapy, 74 Gy in 37 fractions, starts in ten days.
   - Report urinary burning, frequency, or bowel urgency during treatment to radiation oncology.
2. **Androgen deprivation therapy** (Z79.899). Testosterone 18 ng/dL, at the castrate target. Mild hot flashes and fatigue; weight up 1.2 kg; blood pressure 134/78 mm Hg. Vitamin D is now 34 ng/mL. **S**
   - Second leuprolide 22.5 mg injection given today; this completes the six-month course.
   - Continue cholecalciferol 1000 units daily.
   - Keep walking and resistance exercise for fatigue, weight, and bone.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months | Completed today | 0.9 ng/mL, down from 6.4 |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 18 ng/dL, castrate |
| Laboratory | 25-hydroxyvitamin D | Three months after starting a supplement | Completed today | 34 ng/mL, up from 26 |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline four months ago; next in eight months |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline three months ago |
| Examination | Blood pressure, weight, and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 134/78 mm Hg; weight 81.6 kg, up 1.2 kg since starting; no cardiac symptoms |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Mild hot flashes three or four times a week; mild afternoon fatigue; no treatment wanted |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Cognition | Periodically on androgen deprivation | Up to date | Mini-Cog 5 of 5 at the wellness visit five weeks ago; no change reported |
| Survey | Urinary symptoms | Before radiotherapy, then every follow-up visit | Completed today | Mild frequency, unchanged from the baseline IPSS of 7 |
| Survey | Bowel function before radiotherapy | Baseline before radiotherapy, then every visit after it | Deferred | Not asked today, a deviation from the protocol; the visit was taken up by the androgen deprivation results and the radiotherapy plan. To be checked at the next visit |
| Medication safety | Second leuprolide injection | Every twelve weeks for two doses | Completed today | Given today in this clinic |
| Self-management | Physical activity and calcium intake | Every visit | Completed today | Walking every morning; resistance exercise twice a week; calcium from food |

## Goal progress

- Reach an informed, shared decision on treatment after hearing every reasonable option, including observation. Outcome by 2026-04-14: Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation. **S**
- Complete six months of androgen deprivation and the course of radiotherapy with side effects managed. In progress; target 2026-10-27. **S**
- Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise. Outcome by 2026-07-14: Femoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily. **S**
- PSA falling after radiotherapy, with a written surveillance plan. In progress; target 2026-10-27. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022), American Urological Association and American Society for Radiation Oncology
- Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014), American Cancer Society
- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge

## Follow-up

- Radiotherapy from ten days' time, with weekly radiation oncology review. Primary care follow-up six weeks after radiotherapy ends, with PSA and testosterone. **S**
- Next scheduled visit 2026-10-27: follow-up six weeks after radiotherapy: PSA, urinary and bowel effects, end of androgen deprivation, and the surveillance plan. **S**
